Acute Left Heart Failure Following Transcatheter Tricuspid Valve Replacement
Abstract
Transcatheter tricuspid valve replacement has demonstrated efficacy in reducing the severity of tricuspid regurgitation and improving functional capacity. However, postoperative complications require further investigation. We present 2 cases of patients who developed acute left heart failure following transcatheter tricuspid valve replacement. Both patients presented with clinical manifestations including dyspnea, pulmonary crackles, hypoxemia, bilateral pulmonary edema on chest radiography, and elevated N-terminal pro-B-type natriuretic peptide levels. Notably, diuretic therapy combined with inotropic agents and noninvasive ventilatory support was effective in improving symptoms. The underlying mechanism of this complication is related to an abrupt increase in right ventricular output that exceeds the left ventricle's capacity to accommodate. Potential risk factors include left ventricular diastolic dysfunction and small left ventricular dimensions. Importantly, acute left heart failure has also been observed following other right-sided heart procedures with similar mechanisms. To prevent and manage this complication, comprehensive perioperative management is crucial, including identifying high-risk factors preoperatively and actively treating heart failure postoperatively.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.